A5080821885- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Intensive Care Unit Cognitive Disorders
- Parkinson's Disease Mechanisms and Treatments
- Amyotrophic Lateral Sclerosis Research
- Frailty in Older Adults
- Anesthesia and Neurotoxicity Research
- Prion Diseases and Protein Misfolding
- Cellular transport and secretion
- Cardiac, Anesthesia and Surgical Outcomes
- Folate and B Vitamins Research
- Mitochondrial Function and Pathology
- Cholinesterase and Neurodegenerative Diseases
- Biomedical and Engineering Education
- Health and Medical Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Functional Brain Connectivity Studies
- Health Systems, Economic Evaluations, Quality of Life
- Genetic Neurodegenerative Diseases
- Diet and metabolism studies
- Mobile Health and mHealth Applications
- S100 Proteins and Annexins
- Tryptophan and brain disorders
- Nutritional Studies and Diet
- Neurogenetic and Muscular Disorders Research
Universitätsmedizin Göttingen
2019-2025
University of Göttingen
2020-2025
German Centre for Cardiovascular Research
2023-2025
University and Rehabilitation Clinics Ulm
2017-2025
Universität Ulm
2015-2024
University Hospital Ulm
2014-2024
Landscape Research Group
2023
Authorised Association Consortium
2023
Medical University of Vienna
2009-2019
University of Oslo
2018
sorLA (sorting protein-related receptor) is a type-1 membrane protein of unknown function that expressed in neurons. Its homology to sorting receptors shuttle between the plasma membrane, endosomes, and Golgi suggests related neuronal trafficking processes. Because expression reduced brain patients with Alzheimer's disease (AD), we tested involvement this receptor intracellular transport processing amyloid precursor (APP) β-peptide (Aβ), principal component senile plaques. We demonstrate...
Souvenaid aims to improve synapse formation and function. An earlier study in patients with Alzheimer's disease (AD) showed that increased memory performance after 12 weeks drug-naïve mild AD. The Souvenir II was a 24
<h3>Objectives</h3> Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve diagnostic pathway, patient stratification and monitoring. The aim this study was validate candidate markers MND in cerebrospinal fluid (CSF) specify cut-offs based on large cohorts by especially considering patients who were seen under initial differential (MND mimics). <h3>Methods</h3> In a prospective study, we investigated CSF 455 neurofilament light chain (NfL), phosphorylated...
Reliable blood biomarkers for Alzheimer’s disease (AD) are missing. We measured astroglial GFAP in patients with AD ( n = 28), frontotemporal dementia (bvFTD, 35), Parkinson’s 11), Lewy body dementias 19), and controls 34). Serum was increased p < 0.001) DLB/PDD 0.01), cerebrospinal fluid all neurodegenerative diseases 0.001). correlated the Mini-Mental State Examination score r= –0.42, might be a follow-up marker clinical trials. Sensitivity specificity of serum versus bvFTD 89% 79%...
Objective To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS). Methods This single-centre, prospective, longitudinal study included following patients: 124 patients with ALS; 50 without neurodegenerative diseases; 44 conditions differential diagnosis ALS (disease controls); 65 other diseases (20 frontotemporal dementia, 20 Alzheimer’s disease, 19 Parkinson’s 6 Creutzfeldt-Jakob disease (CJD)). Serum NFL levels...
One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of pathology are important for health care planning clinical trial design. To estimate the prevalence abnormality persons with normal cognition, subjective cognitive decline, mild impairment, or AD dementia to examine potential implications cutoff methods,...
<h3>Importance</h3> Neurofibrillary tangles composed of aggregated tau protein are one the neuropathological hallmarks Alzheimer disease (AD) and correlate with clinical severity. Monoclonal antibodies targeting may have potential to ameliorate AD progression by slowing or stopping spread and/or accumulation pathological tau. <h3>Objective</h3> To evaluate safety efficacy monoclonal anti-tau antibody semorinemab in prodromal mild AD. <h3>Design, Setting, Participants</h3> This phase 2...
There is a great need for fully automated plasma assays that can measure amyloid beta (Aβ) pathology and predict future Alzheimer's disease (AD) dementia.
BACE is a transmembrane protease with beta-secretase activity that cleaves the amyloid precursor protein (APP). After cleavage, APP becomes substrate for gamma-secretase, leading to release of amyloid-beta peptide (Abeta), which accumulates in senile plaques Alzheimer disease. and are co-internalized from cell surface early endosomes. also known interact at be internalized by low density lipoprotein receptor-related (LRP), multifunctional endocytic signaling receptor. Using new fluorescence...
Background: Recently, TAR DNA-binding protein 43 (TDP-43) was identified as the major component of ubiquitin-positive tau-negative neuronal and glial inclusions in most common form frontotemporal lobar degeneration (FTLD) amyotrophic lateral sclerosis (ALS).It demonstrated that different TDP-43 profiles correspond to clinical phenotypes FTLD or ALS subgroups, differential diagnostic potential suggested.Objectives: To examine cerebrospinal fluid (CSF) analyze whether it could serve a...
Amyloid plaques are formed by aggregates of amyloid-beta-peptide, a 37-43-amino acid fragment (primarily Abeta(40) and Abeta(42)) generated proteolytic processing the amyloid precursor protein (APP) beta- gamma-secretases. A type I transmembrane aspartyl protease, BACE (beta-site APP cleaving enzyme), has been identified to be beta-secretase. is targeted through secretory pathway plasma membrane where it can internalized endosomes. The carboxyl terminus contains di-leucine-based signal for...
sorLA is a recently identified neuronal receptor for amyloid precursor protein (APP) that known to interact with APP and affect its intracellular transport processing. Decreased levels of in the brain Alzheimer's disease (AD) patients elevated amyloid-β peptide (Aβ) sorLA-deficient mice point importance this neurodegenerative disorder. We analyzed cleavage an APP-shedding assay found both and, surprisingly, tail construct inhibited β-site APP-cleaving enzyme (BACE)-dependent manner. In line...
Alzheimer's disease is characterized by the deposition of amyloid-β peptide in brain. N-terminal truncation resulting formation AβN3pE and phosphorylation at serine 8 have been reported to modify aggregation properties amyloid-β. Biochemically, soluble, dispersible, membrane-associated, insoluble, plaque-associated aggregates distinguished. Soluble dispersible are both mixture with extracellular or intracellular fluid but can be cleared from proteins solution ultracentrifugation. To clarify...
The aim of this study was to assess the agreement between data on cerebral amyloidosis, derived using Pittsburgh compound B positron emission tomography and (i) multi-laboratory INNOTEST enzyme linked immunosorbent assay cerebrospinal fluid concentrations amyloid-β42; (ii) centrally measured amyloid-β42 a Meso Scale Discovery assay; (iii) an antibody-independent mass spectrometry-based reference method. Moreover, we examined hypothesis that discordance amyloid biomarker measurements may be...
In addition to motor neurone degeneration, up 50% of amyotrophic lateral sclerosis (ALS) patients present with cognitive decline. Understanding the neurobiological changes underlying these deficits is critical, as cognitively impaired exhibit a shorter survival time from symptom onset. Given pathogenic role synapse loss in other neurodegenerative diseases which decline apparent, such Alzheimer's disease, we aimed assess synaptic integrity ALS brain. Here, have applied unique combination...
α-Synuclein (αSyn) is a major constituent of proteinaceous aggregates in neurodegenerative diseases such as Parkinson′s disease (PD) and potential biomarker candidate for diagnosis treatment effects. However, studies about αSyn cerebrospinal fluid (CSF) are inconsistent mainly based on immunological assays. Quantitative information β-synuclein (βSyn) γ-synuclein (γSyn) CSF not available.Here, we present an alternative method the simultaneous quantification αSyn, βSyn γSyn by multiple...
Neurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, staging and prediction outcome. We aimed at determining the origin differential diagnostic prognostic potential putative marker microglial activation chitotriosidase (CHIT1).Altogether 316 patients were included, comprising with sporadic ALS, ALS mimics (disease controls (DCo)), frontotemporal lobar degeneration (FTLD), Creutzfeldt-Jakob (CJD), Alzheimer's (AD),...
<h3>Objective</h3> To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up patients behavioral variant frontotemporal dementia (bvFTD). <h3>Methods</h3> Blood NfL levels from 74 bvFTD, 26 Alzheimer disease (AD), 17 mild cognitive impairment (MCI), 15 healthy controls (Con) at baseline were determined analyzed for diagnostic potential in relation to assessment (Clinical Dementia Rating Scale Sum Boxes [CDR-SOB],...